Inulin
As of the edition of 20 October 2026, Inulin is a drug: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Unknown
- Brand name
- Inulead
- First approved
- 1 January 1982 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Fuji Yakuhin; 2 holders in all
- Registered trials
- 13, 1 stopped early
- Disease areas
- Cancer; Nutrition and metabolism; Digestive system; Immune system; Infections; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 1 | 1 | 1 |
| Phase 1 | 3 | 1 | 0 | 0 |
| Phase 2 | 4 | 1 | 2 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Iso-Tex Diagnostics | Acquired holder | 2004 to now |
| Fuji Yakuhin | Applicant | 2021 to now |